CVS Ousts Karen Lynch as C.E.O. and Shares Fall

Published On Oct 18, 2024, 10:05 AM

CVS Health has ousted its CEO, Karen Lynch, due to sluggish growth and disappointing financial performance. Following her removal, the company's shares fell sharply as they scrapped previous earnings forecasts amid rising medical costs, particularly from Aetna, CVS's insurance division. The board has appointed David Joyner, currently the head of CVS Caremark, as the new CEO, citing his knowledge of the business as key to navigating its current struggles. The company is also planning to lay off approximately 3,000 employees and has seen a significant drop in its stock value this year.

Stock Forecasts

Given the abrupt leadership change and the negative outlook on earnings due to elevated costs, CVS is facing significant challenges that could deter investors. The likelihood of continued volatility is high as the company restructures and addresses management and operational issues.

Related News

CVS Health tapped industry veteran David Joyner to become CEO and turnaround the struggling business.

Shares fell 11% in premarket trading, adding to this year's losses, as CVS also forecast quarterly adjusted profit below estimates. Shareholders have become increasingly nervous about repeated profit forecast cuts this year as its drugstores face reimbursement pressures and high costs hit the health insurance industry. Investor Glenview Capital said earlier this month it was working with CVS to help improve operations as the company faces one of the most challenging periods in its six-decade history.

Retail pharmacies will never be obsolete, according to an analyst. But the industry needs to take a hard look at how many stores are needed and what items they should sell.

CVS
WBA